CA2705612A1 - Radiation protection and treatment for exposure to gamma-radiation - Google Patents

Radiation protection and treatment for exposure to gamma-radiation Download PDF

Info

Publication number
CA2705612A1
CA2705612A1 CA2705612A CA2705612A CA2705612A1 CA 2705612 A1 CA2705612 A1 CA 2705612A1 CA 2705612 A CA2705612 A CA 2705612A CA 2705612 A CA2705612 A CA 2705612A CA 2705612 A1 CA2705612 A1 CA 2705612A1
Authority
CA
Canada
Prior art keywords
branched
chain
alkyl
straight
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2705612A
Other languages
English (en)
French (fr)
Inventor
Wenlin Deng
Veeresa Gududuru
Gangadhar Durgam
Gabor Tigyi
Duane Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2705612A1 publication Critical patent/CA2705612A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measurement Of Radiation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2705612A 2006-11-15 2007-11-15 Radiation protection and treatment for exposure to gamma-radiation Abandoned CA2705612A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86587106P 2006-11-15 2006-11-15
US60/865,871 2006-11-15
PCT/US2007/084875 WO2008140574A2 (en) 2006-11-15 2007-11-15 Radiation protection and treatment for exposure to gamma-radiation

Publications (1)

Publication Number Publication Date
CA2705612A1 true CA2705612A1 (en) 2008-11-20

Family

ID=40002804

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2705612A Abandoned CA2705612A1 (en) 2006-11-15 2007-11-15 Radiation protection and treatment for exposure to gamma-radiation

Country Status (6)

Country Link
EP (1) EP2099469A4 (https=)
JP (1) JP2010510238A (https=)
AU (1) AU2007353320B2 (https=)
CA (1) CA2705612A1 (https=)
IL (1) IL198789A0 (https=)
WO (1) WO2008140574A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015102856A1 (en) * 2013-12-30 2015-07-09 Rxbio Inc. Crystalline salts of (z)-o-octadec-9-en-1-yl o,o-dihydrogen phosphorothioate
US20170007559A1 (en) * 2015-07-12 2017-01-12 The University Of Tennessee Research Foundation Compositions and methods for protecting colonic epithelial barrier function
JPWO2018016523A1 (ja) * 2016-07-20 2019-05-09 国立大学法人 長崎大学 新規放射線防護剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE540044T1 (de) 2003-10-09 2012-01-15 Univ Tennessee Res Foundation Lpa-rezeptor-agonisten und antagonisten und verwendungsverfahren dafür
AU2006270066A1 (en) * 2005-07-19 2007-01-25 University Of Tennessee Research Foundation LPA2 receptor agonist inhibitors of CFTR

Also Published As

Publication number Publication date
AU2007353320A1 (en) 2008-11-20
EP2099469A2 (en) 2009-09-16
JP2010510238A (ja) 2010-04-02
WO2008140574A2 (en) 2008-11-20
IL198789A0 (en) 2011-08-01
EP2099469A4 (en) 2013-02-27
AU2007353320B2 (en) 2014-01-23
WO2008140574A3 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
Deng et al. The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury
Meuillet et al. Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues
Lv et al. Berberine inhibits doxorubicin-triggered cardiomyocyte apoptosis via attenuating mitochondrial dysfunction and increasing Bcl-2 expression
Barbier-Torres et al. Stabilization of LKB1 and Akt by neddylation regulates energy metabolism in liver cancer
Kim et al. Targeting cancer metabolism by simultaneously disrupting parallel nutrient access pathways
Wu et al. 5-Androstenediol prevents radiation injury in mice by promoting NF-κB signaling and inhibiting AIM2 inflammasome activation
EP2637649A2 (en) Compounds and methods for treating pain
Wang et al. Pitavastatin slows tumor progression and alters urine-derived volatile organic compounds through the mevalonate pathway
CA2755191A1 (en) Kinase protein binding inhibitors
Pollizzi et al. Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis
US20190142835A1 (en) Inhibition of autophagy using phospholipase a2 inhibitors
US20230068698A1 (en) Combination therapy for cancer
EP1954254A2 (en) Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis
Liu et al. Conversion of 2-deoxyglucose-induced growth inhibition to cell death in normoxic tumor cells
Zhao et al. Sphingadienes show therapeutic efficacy in neuroblastoma in vitro and in vivo by targeting the AKT signaling pathway
Chen et al. Carbidopa suppresses estrogen receptor-positive breast cancer via AhR-mediated proteasomal degradation of ERα
AU2007353320B2 (en) Radiation protection and treatment for exposure to gamma-radiation
Brindley et al. Autotaxin—An enzymatic augmenter of malignant progression linked to inflammation
Liu et al. Inhibiting checkpoint kinase 1 protects bone from bone resorption by mammary tumor in a mouse model
EP4139484B1 (en) Therapeutic methods for preventing tumor metastasis and tumor recurrence
Rajpurohit et al. Moving towards dawn: KRas signaling and treatment in pancreatic ductal adenocarcinoma
Katsumi et al. Development of polyethylene glycol-conjugated alendronate, a novel nitrogen-containing bisphosphonate derivative: evaluation of absorption, safety, and effects after intrapulmonary administration in rats
Erdogan et al. RETRACTED ARTICLE: Rottlerin and genistein inhibit neuroblastoma cell proliferation and invasion through EF2K suppression and related protein pathways
WO2015028662A1 (en) Compositions and methods for characterization and amelioration of rheumatoid arthritis
Ma et al. Karanjin counteracts OVX-induced bone loss by dual regulating bone remodeling

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20141117